Can patent duration hinder medical innovation
Author
Abstract
Suggested Citation
DOI: 10.1007/s10754-016-9198-0
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
References listed on IDEAS
- Juan-José Ganuza & Gerard Llobet & Beatriz Domínguez, 2009.
"R& D in the Pharmaceutical Industry: A World of Small Innovations,"
Management Science, INFORMS, vol. 55(4), pages 539-551, April.
- Beatriz Domínguez & Juan José Ganuza & Gerard Llobet, 2005. "R&D in the pharmaceutical industry: A world of small innovations," Economics Working Papers 936, Department of Economics and Business, Universitat Pompeu Fabra.
- Beatriz Domínguez & Juan-José Ganuza & Gerard Llobet, 2006. "R&D in the Pharmaceutical Industry: A World of Small Innovations," Working Papers wp2006_0601, CEMFI.
- González, Paula & Macho-Stadler, Inés & Pérez-Castrillo, David, 2016.
"Private versus social incentives for pharmaceutical innovation,"
Journal of Health Economics, Elsevier, vol. 50(C), pages 286-297.
- Paula González & Ines Macho-Stadler & David Pérez-Castrillo, 2015. "Private versus Social Incentives for Pharmaceutical Innovation," CESifo Working Paper Series 5672, CESifo.
- Paula González & David Pérez-Castrillo & Inés Macho-Stadler, 2016. "Private versus Social Incentives for Pharmaceutical Innovation," Working Papers 860, Barcelona School of Economics.
- Paula González & Inés Macho-Stadler & David Pérez-Castrillo, 2015. "Private versus Social Incentives for Pharmaceutical Innovation," Working Papers 15.07, Universidad Pablo de Olavide, Department of Economics.
- Denicolo, Vincenzo, 1999. "The optimal life of a patent when the timing of innovation is stochastic," International Journal of Industrial Organization, Elsevier, vol. 17(6), pages 827-846, August.
- Banri ITO & Tatsufumi YAMAGATA, 2007.
"Who Develops Innovations In Medicine For The Poor? Trends In Patent Applications Related To Medicines For Hiv/Aids, Tuberculosis, Malaria, And Neglected Diseases,"
The Developing Economies, Institute of Developing Economies, vol. 45(2), pages 141-171, June.
- Ito, Banri & Yamagata, Tatsufumi, 2005. "Who Develops Innovations in Medicine for the Poor? Trends in Patent Applications Related to Medicines for HIV/AIDS, Tuberculosis, Malaria and Neglected Diseases," IDE Discussion Papers 24, Institute of Developing Economies, Japan External Trade Organization(JETRO).
- Matsushima, Hitoshi, 2001.
"Multimarket Contact, Imperfect Monitoring, and Implicit Collusion,"
Journal of Economic Theory, Elsevier, vol. 98(1), pages 158-178, May.
- Hitoshi Matsushima, 1998. "Multimarket Contact, Imperfect Monitoring, and Implicit Collusion," CIRJE F-Series CIRJE-F-24, CIRJE, Faculty of Economics, University of Tokyo.
- Hudson, John, 2000. "Generic take-up in the pharmaceutical market following patent expiry: A multi-country study," International Review of Law and Economics, Elsevier, vol. 20(2), pages 205-221, June.
- Jean Tirole, 1988. "The Theory of Industrial Organization," MIT Press Books, The MIT Press, edition 1, volume 1, number 0262200716, December.
- Office of Health Economics, 2007. "The Economics of Health Care," For School 001490, Office of Health Economics.
- Joan-Ramon Borrell, 2007. "Pricing and patents of HIV/AIDS drugs in developing countries," Applied Economics, Taylor & Francis Journals, vol. 39(4), pages 505-518.
- Francesca Cornelli & Mark Schankerman, 1999. "Patent Renewals and R&D Incentives," RAND Journal of Economics, The RAND Corporation, vol. 30(2), pages 197-213, Summer.
- Arleen Leibowitz & Neeraj Sood, 2007. "Market power and state costs of HIV/AIDS drugs," International Journal of Health Economics and Management, Springer, vol. 7(1), pages 59-71, March.
- Grabowski, Henry G & Vernon, John M, 1992. "Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act," Journal of Law and Economics, University of Chicago Press, vol. 35(2), pages 331-350, October.
- Horowitz, Andrew W & Lai, Edwin L-C, 1996. "Patent Length and the Rate of Innovation," International Economic Review, Department of Economics, University of Pennsylvania and Osaka University Institute of Social and Economic Research Association, vol. 37(4), pages 785-801, November.
- B. Douglas Bernheim & Michael D. Whinston, 1990. "Multimarket Contact and Collusive Behavior," RAND Journal of Economics, The RAND Corporation, vol. 21(1), pages 1-26, Spring.
- Michael Kremer, 2002. "Pharmaceuticals and the Developing World," Journal of Economic Perspectives, American Economic Association, vol. 16(4), pages 67-90, Fall.
Citations
Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
Cited by:
- Le, Son & Sukhatme, Neel U., 2020. "Reaching for mediocrity: Competition and stagnation in pharmaceutical innovation," International Review of Law and Economics, Elsevier, vol. 64(C).
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- Patricia M. Danzon & Eric L. Keuffel, 2014. "Regulation of the Pharmaceutical-Biotechnology Industry," NBER Chapters, in: Economic Regulation and Its Reform: What Have We Learned?, pages 407-484, National Bureau of Economic Research, Inc.
- Cruz-García, Paula & Fernández de Guevara, Juan & Maudos, Joaquín, 2021. "Bank competition and multimarket contact intensity," Journal of International Money and Finance, Elsevier, vol. 113(C).
- Anupam B. Jena & Stéphane Mechoulan & Tomas J. Philipson, 2010. "Altruism and Innovation in Health Care," Journal of Law and Economics, University of Chicago Press, vol. 53(3), pages 497-518.
- Kaplow, Louis & Shapiro, Carl, 2007.
"Antitrust,"
Handbook of Law and Economics, in: A. Mitchell Polinsky & Steven Shavell (ed.), Handbook of Law and Economics, edition 1, volume 2, chapter 15, pages 1073-1225,
Elsevier.
- Louis Kaplow & Carl Shapiro, 2007. "Antitrust," NBER Working Papers 12867, National Bureau of Economic Research, Inc.
- Kaplow, Louis & Shapiro, Carl, 2007. "Antitrust," Competition Policy Center, Working Paper Series qt9pt7p9bm, Competition Policy Center, Institute for Business and Economic Research, UC Berkeley.
- Tomas J. Philipson & Eric Sun, 2008.
"Is the Food And Drug Administration Safe And Effective?,"
Journal of Economic Perspectives, American Economic Association, vol. 22(1), pages 85-102, Winter.
- Tomas J. Philipson & Eric Sun, 2007. "Is the Food and Drug Administration Safe and Effective?," NBER Working Papers 13561, National Bureau of Economic Research, Inc.
- Philipson, Tomas J. & Sun, Eric, 2007. "Is the Food and Drug Administration Safe and Effective?," Working Papers 218, The University of Chicago Booth School of Business, George J. Stigler Center for the Study of the Economy and the State.
- Meghan R. Busse, 2000. "Multimarket Contact and Price Coordination in the Cellular Telephone Industry," Journal of Economics & Management Strategy, Wiley Blackwell, vol. 9(3), pages 287-320, June.
- Jeanine Miklós-Thal, 2011.
"Optimal collusion under cost asymmetry,"
Economic Theory, Springer;Society for the Advancement of Economic Theory (SAET), vol. 46(1), pages 99-125, January.
- Jeanine Thal, 2005. "Optimal Collusion under Cost Asymmetry," Working Papers 2005-36, Center for Research in Economics and Statistics.
- Miklos-Thal, Jeanine, 2008. "Optimal Collusion under Cost Asymmetry," MPRA Paper 11044, University Library of Munich, Germany.
- Pham, Tho & Talavera, Oleksandr & Yang, Junhong, 2016.
"Multimarket Competition and Profitability: Evidence from Ukrainian banking,"
MPRA Paper
72376, University Library of Munich, Germany.
- Pham, Tho & Talavera, Oleksandr & Yang, Junhong, 2016. "Multimarket Competition and Profitability: Evidence from Ukrainian banking," MPRA Paper 78763, University Library of Munich, Germany, revised 01 Apr 2017.
- Tho Pham & Oleksandr Talavera & Junhong Yang, 2018. "Multimarket Competition and Profitability: Evidence from Ukrainian banking," Working Papers 2018-02, Swansea University, School of Management.
- Javier Coronado & Sergi Jiménez-Martín & Pedro L. Marín, 2007.
"Multimarket contact in pharmaceutical markets,"
Economics Working Papers
1033, Department of Economics and Business, Universitat Pompeu Fabra, revised Jul 2007.
- Javier Coronado & Sergi Jiménez Martín & Pedro L. Marín, 2008. "Multimarket Contact in Pharmaceutical Markets," Working Papers 2008-20, FEDEA.
- Javier Coronado & Sergi Jiménez-Martín & Pedro L. Marín, 2007. "Multimarket Contact in Pharmaceutical Markets," UFAE and IAE Working Papers 698.07, Unitat de Fonaments de l'Anàlisi Econòmica (UAB) and Institut d'Anàlisi Econòmica (CSIC), revised 18 Jul 2007.
- Javier Coronado & Sergi Jiménez-MartÃn, 2015. "Multimarket Contact in Pharmaceutical Markets," Working Papers 303, Barcelona School of Economics.
- Joan Costa-i-Font & Alistair McGuire & Nebibe Varol, 2011.
"Does Pharmaceutical Price Regulation Affect the Adoption of Generic Competition? Evidence from the OECD, 1999-2008,"
CESifo Working Paper Series
3441, CESifo.
- Costa-i-Font, Joan & Varol, Nebibe & McGuire, Alistair, 2011. "Does pharmaceutical price regulation affect the adoption of generic competition?: evidence from the OECD, 1999-2008," LSE Research Online Documents on Economics 37537, London School of Economics and Political Science, LSE Library.
- Davide Vannoni, 2000.
"The diversifield firm: non formal theories versus formal models,"
ECONOMIA E POLITICA INDUSTRIALE, FrancoAngeli Editore, vol. 2000(106).
- Davide Vannoni, 1998. "The diversified firm: non formal theories versus formal models," CERIS Working Paper 199806, CNR-IRCrES Research Institute on Sustainable Economic Growth - Torino (TO) ITALY - former Institute for Economic Research on Firms and Growth - Moncalieri (TO) ITALY.
- Mario Pezzino, 2010. "Hospital competition when patients have different willingness to pay for quality," Economics Discussion Paper Series 1014, Economics, The University of Manchester.
- Alice M. Ellyson & Anirban Basu, 2018. "The New Prescription Drug Paradox: Pipeline Pressure and Rising Prices," NBER Working Papers 24387, National Bureau of Economic Research, Inc.
- Armel Jacques, 2024. "Increased fines for repeat offenders and conglomerate dynamics," TEPP Working Paper 2024-06, TEPP.
- Laura Magazzini & Fabio Pammolli & Gianluca Papa & Nicola Carmine Salerno, 2005. "Generici vs. Branded: confronto internazionale su prodotti off-patent rimborsati dal SSN," Working Papers CERM 01-2005, Competitività, Regole, Mercati (CERM).
- Haizhen Lin & Ian M. McCarthy, 2023.
"Multimarket Contact in Health Insurance: Evidence from Medicare Advantage,"
Journal of Industrial Economics, Wiley Blackwell, vol. 71(1), pages 212-255, March.
- Haizhen Lin & Ian M. McCarthy, 2018. "Multimarket Contact in Health Insurance: Evidence from Medicare Advantage," NBER Working Papers 24486, National Bureau of Economic Research, Inc.
- Makoto Kakinaka & Ryuta Kato, 2013.
"Regulated medical fee schedule of the Japanese health care system,"
International Journal of Health Economics and Management, Springer, vol. 13(3), pages 301-317, December.
- Makoto Kakinaka & Ryuta Ray Kato, 2011. "Regulated Medical Fee Schedule of the Japanese Health Care System," Working Papers EMS_2011_13, Research Institute, International University of Japan.
- Mason, Charles F. & Phillips, Owen R., 2000. "Vertical integration and collusive incentives: an experimental analysis," International Journal of Industrial Organization, Elsevier, vol. 18(3), pages 471-496, April.
- Matsushima, Hitoshi & Miyazaki, Koichi & Yagi, Nobuyuki, 2010.
"Role of linking mechanisms in multitask agency with hidden information,"
Journal of Economic Theory, Elsevier, vol. 145(6), pages 2241-2259, November.
- Hitoshi Matsushima & Koichi Miyazaki & Nobuyuki Yagi, 2006. "Role of Linking Mechanisms in Multitask Agency with Hidden Information," CIRJE F-Series CIRJE-F-401, CIRJE, Faculty of Economics, University of Tokyo.
- Hitoshi Matsushima & Koichi Miyazaki & Nobuyuki Yagi, 2010. "Role of Linking Mechanisms in Multitask Agency with Hidden Information," CIRJE F-Series CIRJE-F-721, CIRJE, Faculty of Economics, University of Tokyo.
- Hitoshi Matsushima & Koichi Miyazaki & Nobuyuki Yagi, 2010. "Role of Linking Mechanisms in Multitask Agency with Hidden Information," CARF F-Series CARF-F-209, Center for Advanced Research in Finance, Faculty of Economics, The University of Tokyo.
- Chih‐Hai Yang, 2008. "Effects Of Strengthening Intellectual Property Rights In Newly Industrialized Economies: Evidence From Taiwan’S 1994 Patent Reform," Contemporary Economic Policy, Western Economic Association International, vol. 26(2), pages 259-275, April.
More about this item
Keywords
Me-too drugs; Medical innovation; Patent duration; Collusion;All these keywords.
JEL classification:
- I1 - Health, Education, and Welfare - - Health
- L1 - Industrial Organization - - Market Structure, Firm Strategy, and Market Performance
Statistics
Access and download statisticsCorrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:kap:ijhcfe:v:16:y:2016:i:4:d:10.1007_s10754-016-9198-0. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.